Use of antipsychotics - An analysis of lifetime treatment in 66 patients with psychoses

Psychiatry Research

Volumn 187, Issue 1-2, 2011, Pages 80-88

  Jönsson, Erik G ^a   Saetre, Peter ^a   Vares, Maria ^a   Strålin, Pontus ^a   Levander, Sten ^b   Lindström, Eva ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MALMÖ UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antipsychotic drugs; Lifetime; Poly pharmacy; Retrospective; Schizophrenia

Indexed keywords

ALIMEMAZINE; ARIPIPRAZOLE; CHLORPROMAZINE; CHLORPROTHIXENE; CLOPENTHIXOL; CLOZAPINE; DIXYRAZINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; MELPERONE; MOPERONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; REMOXIPRIDE; RISPERIDONE; RITANSERIN; SULPIRIDE; THIORIDAZINE; TRIFLUOPERAZINE; ZIPRASIDONE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; BIPOLAR DISORDER; DESCRIPTIVE RESEARCH; DISEASE SEVERITY; DRUG USE; DRUG WITHDRAWAL; EXPECTATION; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NATURALISTIC INQUIRY; ONSET AGE; PATIENT ATTITUDE; PHYSICIAN ATTITUDE; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RETROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SWEDEN; TREND STUDY; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIPYRETICS; DRUG PRESCRIPTIONS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 79953125603     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2010.10.027     Document Type: Article

References (50)

1. Agartz I., Sedvall G.C., Terenius L., Kulle B., Frigessi A., Hall H., Jönsson E.G. BDNF gene variants and brain morphology in schizophrenia. American Journal of Medical Genetics. Part B: Neuropsychiatric Genetics 2006, 141B:513-523.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1987, APA, Washington, DC. Third Edition-Revised.
3. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1995, APA, Washington, DC. Fourth Edition, International Version.
4. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS) 1983, University of Iowa, Iowa City.
5. Andreasen N.C. The Scale for the Assessment of Positive Symptoms (SAPS) 1984, University of Iowa, Iowa City.
6. Andreou D., Saetre P., Lundmark P., Hansen T., Timm S., Melle I., Djurovic S., Andreassen O.A., Werge T., Hall H., Agartz I., Terenius L., Jönsson E.G. Tyrosine hydroxylase (TH) Val81Met polymorphism: lack of association with schizophrenia. Psychiatric Genetics 2009, 19:273-274.
7. Baandrup L., Gasse C., Jensen V.D., Glenthoj B.Y., Nordentoft M., Lublin H., Fink-Jensen A., Lindhardt A., Mortensen P.B. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. The Journal of Clinical Psychiatry 2010, 71:103-108.
8. Bingefors K., Isacson D., Lindström E. Dosage patterns of antipsychotic drugs for the treatment of schizophrenia in Swedish ambulatory clinical practice--a highly individualized therapy. Nordic Journal of Psychiatry 2003, 57:263-269.
9. Bland R.C., Orn H. 14-Year outcome in early schizophrenia. Acta Psychiatrica Scandinavica 1978, 58:327-338.
10. Cookson J. The development of new drugs for the treatment of schizophrenia. British Journal of Hospital Medicine 1987, 38:542-548.
11. Crow T.J. The continuum of psychosis and its implication for the structure of the gene. The British Journal of Psychiatry 1986, 149:419-429.
12. Davis, J.M., Garver, D.L., 1978. Neuroleptics: Clinical Use in Psychiatry. Plenum Press, New York.
13. Ekholm B., Ekholm A., Adolfsson R., Vares M., Ösby U., Sedvall G.C., Jönsson E.G. Evaluation of diagnostic procedures in Swedish patients with schizophrenia and related psychoses. Nordic Journal of Psychiatry 2005, 59:457-464.
14. Fleischhacker W.W. New drugs for schizophrenic patients. Clinical Courier 1994, 12:6-7.
15. Hall H., Lawyer G., Sillén A., Jönsson E.G., Agartz I., Terenius L., Arnborg S. Potential genetic variants in schizophrenia - a Bayesian analysis. The World Journal of Biological Psychiatry 2007, 8:12-22.
16. Hamshere M.L., Bennett P., Williams N., Segurado R., Cardno A., Norton N., Lambert D., Williams H., Kirov G., Corvin A., Holmans P., Jones L., Jones I., Gill M., O'Donovan M.C., Owen M.J., Craddock N. Genomewide linkage scan in schizoaffective disorder: significant evidence for linkage at 1q42 close to DISC1, and suggestive evidence at 22q11 and 19p13. Archives of General Psychiatry 2005, 62:1081-1088.
17. Johnson D.A. Antipsychotic medication: clinical guidelines for maintenance therapy. The Journal of Clinical Psychiatry 1985, 46:6-15.
18. Jönsson E.G., Abou Jamra R., Schumacher J., Flyckt L., Edman G., Forslund K., Mattila-Evenden M., Rylander G., Åsberg M., Bjerkenstedt L., Wiesel F.-A., Propping P., Cichon S., Nöthen M.M., Sedvall G.C. No association between a putative functional promoter variant in the dopamine β-hydroxylase gene and schizophrenia. Psychiatric Genetics 2003, 13:175-178.
19. Jönsson E.G., Cichon S., Schumacher J., Abou Jamra R., Schulze T.G., Deschner M., Forslund K., Hall H., Propping P., Czerski P.M., Dmitrak-Weglarz M., Kapelski P., Driessen M., Maier W., Hauser J., Rietschel M., Nöthen M.M. Association study of a functional promoter polymorphism in the XBP1 gene and schizophrenia. American Journal of Medical Genetics 2006, 141B:71-75.
20. Jönsson E.G., Edman-Ahlbom B., Sillén A., Gunnar A., Kulle B., Frigessi A., Vares M., Ekholm B., Wode-Helgodt B., Schumacher J., Cichon S., Agartz I., Sedvall G.C., Hall H., Terenius L. Brain-derived neurotrophic factor gene (BDNF) variants and schizophrenia: an association study. Progress in Neuropsychopharmacology & Biological Psychiatry 2006, 30:924-933.
21. Jönsson E.G., Flyckt L., Burgert E., Crocq M.-A., Forslund K., Mattila-Evenden M., Rylander G., Åsberg M., Nimgaonkar V.L., Edman G., Bjerkenstedt L., Wiesel F.-A., Sedvall G.C. Dopamine D3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis. Psychiatric Genetics 2003, 13:1-12.
22. Jönsson E.G., Larsson K., Vares M., Hansen T., Wang A.G., Djurovic S., Rønningen K.S., Andreassen O.A., Agartz I., Werge T., Terenius L., Hall H. Two methylenetetrahydrofolate reductase gene (MTHFR) polymorphisms, schizophrenia and bipolar disorder: an association study. American Journal of Medical Genetics. Part B: Neuropsychiatric Genetics 2008, 147B:976-982.
23. Jönsson E.G., Saetre P., Vares M., Andreou D., Larsson K., Timm S., Rasmussen H.B., Djurovic S., Melle I., Andreassen O.A., Agartz I., Werge T., Hall H., Terenius L. DTNBP1, NRG1, DAOA, DAO and GRM3 polymorphisms and schizophrenia: an association study. Neuropsychobiology 2009, 59:142-150.
24. Jönsson E.G., Sillén A., Vares M., Ekholm B., Terenius L., Sedvall G.C. Dopamine D2 receptor gene Ser311Cys variant and schizophrenia: association study and meta-analysis. American Journal of Medical Genetics 2003, 119B:28-34.
25. Kilzieh N., Todd-Stenberg J.A., Kennedy A., Wood A.E., Tapp A.M. Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting. Journal of Clinical Psychopharmacology 2008, 28:74-77.
26. Lawyer G., Nyman H., Agartz I., Arnborg S., Jönsson E.G., Sedvall G.C., Hall H. Morphological correlates to cognitive dysfunction in schizophrenia as studied with Bayesian regression. BMC Psychiatry 2006, 6:31.
27. Levander S., Eberhard J., Lindström E. Clinical decision-making during 5years of antipsychotic treatment. Acta Psychiatrica Scandinavica. Supplementum 2007, 17-26.
28. Lichtenstein P., Yip B.H., Björk C., Pawitan Y., Cannon T.D., Sullivan P.F., Hultman C.M. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 2009, 373:234-239.
29. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine 2005, 353:1209-1223.
30. Lindström E., Eberhard J., Levander S. Five-year follow-up during antipsychotic treatment: efficacy, safety, functional and social outcome. Acta Psychiatrica Scandinavica. Supplementum 2007, 5-16.
31. Maier W., Lichtermann D., Minges J., Hallmayer J., Heun R., Benckert O., Levinson D.F. Continuity and discontinuity of affective disorders and schizophrenia. Archives of General Psychiatry 1993, 50:871-883.
32. Mancevski B., Keilp J., Kurzon M., Berman R.M., Ortakov V., Harkavy-Friedman J., Rosoklija G., Dwork A.J. Lifelong course of positive and negative symptoms in chronically institutionalized patients with schizophrenia. Psychopathology 2007, 40:83-92.
33. Marchiaro L., Rocca P., LeNoci F., Longo P., Montemagni C., Rigazzi C., Bogetto F. Naturalistic, retrospective comparison between second-generation antipsychotics and depot neuroleptics in patients affected by schizophrenia. The Journal of Clinical Psychiatry 2005, 66:1423-1431.
34. Mojtabai R., Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Archives of General Psychiatry 2010, 67:26-36.
35. Quinn J., Moran M., Lane A., Kinsella A., Waddington J.L. Long-term adaptive life functioning in relation to initiation of treatment with antipsychotics over the lifetime trajectory of schizophrenia. Biological Psychiatry 2000, 48:163-166.
36. Saetre P., Agartz I., De Franciscis A., Lundmark P., Djurovic S., Kähler A., Andreassen O.A., Jakobsen K.D., Rasmussen H.B., Werge T., Hall H., Terenius L., Jönsson E.G. Association between a disrupted-in-schizophrenia 1 (DISC1) single nucleotide polymorphism and schizophrenia in a combined Scandinavian case control sample. Schizophrenia Research 2008, 106:237-241.
37. Saetre P., Lundmark P., Wang A., Hansen T., Rasmussen H.B., Djurovic S., Melle I., Andreassen O.A., Werge T., Agartz I., Hall H., Terenius L., Jönsson E.G. The tryptophan hydroxylase 1 (TPH1) gene, schizophrenia susceptibility and suicidal behavior: a multi-centre case-control study and meta-analysis. American Journal of Medical Genetics. Part B: Neuropsychiatric Genetics 2010, 153B:387-396.
38. Shajahan P., Keith S., Majjiga C., Murphy J., MacRae A., Bashir M., Taylor M. Comparing the effectiveness of aripiprazole and quetiapine in schizophrenia and related psychoses: a naturalistic, retrospective chart review study. The Journal of Clinical Psychiatry 2009, 70:692-698.
39. Stimmel G. Advances in the treatment of psychosis. American Journal of Pharmacology 1987, 159:27-35.
40. Tamagaki C., Sedvall G.C., Jönsson E.G., Okugawa G., Hall H., Pauli S., Agartz I. Altered white to grey matter proportions in the striatum of patients with schizophrenia: a volumetric MRI study. The American Journal of Psychiatry 2005, 162:2315-2321.
41. Tiihonen J., Lonnqvist J., Wahlbeck K., Klaukka T., Niskanen L., Tanskanen A., Haukka J. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009, 374:620-627.
42. Vares M., Ekholm A., Sedvall G.C., Hall H., Jönsson E.G. Characterisation of patients with schizophrenia and related psychosis: evaluation of different diagnostic procedures. Psychopathology 2006, 39:286-295.
43. Vares M., Saetre P., Deng H., Cai G., Liu X., Hansen T., Rasmussen H.B., Werge T., Melle I., Djurovic S., Andreassen O.A., Agartz I., Hall H., Terenius L., Jönsson E.G. Association between methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and age of onset in schizophrenia. American Journal of Medical Genetics. Part B: Neuropsychiatric Genetics 2010, 153B:610-618.
44. Varnäs K., Lawyer G., Jönsson E.G., Kulle B., Nesvåg R., Hall H., Terenius L., Agartz I. Brain-derived neurotrophic factor polymorphisms and frontal cortex morphology in schizophrenia. Psychiatric Genetics 2008, 18:177-183.
45. Weiden P.J. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial. The Journal of Clinical Psychiatry 2007, 68(Suppl 1):12-19.
46. Velligan D.I., Weiden P.J., Sajatovic M., Scott J., Carpenter D., Ross R., Docherty J.P. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. The Journal of Clinical Psychiatry 2009, 70(Suppl 4):1-46. quiz 47-8.
47. White L., Friedman J.I., Bowie C.R., Evers M., Harvey P.D., Parrella M., Mihaila E., Davis K.L. Long-term outcomes in chronically hospitalized geriatric patients with schizophrenia: retrospective comparison of first generation and second generation antipsychotics. Schizophrenia Research 2006, 88:127-134.
48. Wing J.K. Five-year outcome in early schizophrenia. Proceedings of the Royal Society of Medicine 1966, 59:17-18.
49. von Sievers E. En efterundersökning av 111 patienter vårdade för schizofreni första gången under åren 1961-65. Nordisk Psykiatrisk Tidsskrift 1983, 37.
50. World Health Organization, 2007. Collaborating Centre for Drug Statistics Methodology Available at: http://www.whocc.no/atcddd/.